<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="141390">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02107183</url>
  </required_header>
  <id_info>
    <org_study_id>Trial120_A</org_study_id>
    <nct_id>NCT02107183</nct_id>
  </id_info>
  <brief_title>Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial</brief_title>
  <acronym>RINO</acronym>
  <official_title>Impact of Nasal High-flow vs Venturi Mask Oxygen Therapy on Weaning Outcome: a Multicenter, Randomized, Controlled Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Fisher and Paykel Healthcare</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <authority>Italy: Ethics Committee</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether, as compared with the Venturi mask, a
      nasal, high-flow oxygenation device (Optiflow) may reduce the extubation failure rate in
      patients needing oxygen therapy after extubation.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study compares the effects of two devices for oxygen therapy, the nasal, high-flow
      (Optiflow, intervention) and the Venturi mask (control), on the outcome of extubation.
      Available data suggest that Optiflow can improve oxygenation and patient's comfort in
      critically ill patients after extubation. The study hypothesis is that Optiflow may reduce
      the extubation failure rate in these patients.

      In the intervention group, patients fulfilling inclusion criteria and not presenting any of
      the exclusion criteria will receive high-flow oxygen through nasal cannula (Optiflow, Fisher
      &amp; Paykel Healthcare Ltd., New Zealand) after extubation. The oxygen concentration (FiO2)
      will be set to reach an oxygenation target similar to control patients (see below), while
      the gas flow rate will be set at 50 L/min.

      In the control group, patients fulfilling inclusion criteria and not presenting any of the
      exclusion criteria will receive oxygen through a standard Venturi mask after extubation. The
      FiO2 will be set to obtain a arterial oxygen saturation (SpO2) between 92% and 98% (or
      between 88% and 95% in hypercapnic patients). Further FiO2 modifications will be performed
      by the attending physicians to meet the oxygenation target.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date>June 2014</start_date>
  <completion_date type="Anticipated">June 2016</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Prevention</study_design>
  <primary_outcome>
    <measure>Reintubation</measure>
    <time_frame>within 72 hours after extubation or at ICU discharge</time_frame>
    <safety_issue>No</safety_issue>
  </primary_outcome>
  <secondary_outcome>
    <measure>Need for Non-Invasive Ventilation</measure>
    <time_frame>at day 28 after inclusion in the study or at ICU discharge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU length of stay</measure>
    <time_frame>at day 28 from the inclusion in the study or at ICU discharge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital length of stay</measure>
    <time_frame>at day 28 from the inclusion in the study or at hospital discharge</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU readmission</measure>
    <time_frame>at day 28 from inclusion in the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ICU mortality</measure>
    <time_frame>at day 28 from inclusion in the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Hospital mortality</measure>
    <time_frame>at day 28 from inclusion in the study</time_frame>
    <safety_issue>No</safety_issue>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Weaning Failure</condition>
  <condition>Acute Respiratory Failure</condition>
  <arm_group>
    <arm_group_label>Nasal high-flow oxygen therapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High-flow, fully humidified oxygen delivered through nasal cannula (Optiflow, Fisher &amp; Paykel Healthcare) after extubation up to ICU discharge</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Venturi mask oxygen therapy</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Oxygen delivered through standard Venturi mask after extubation up to ICU discharge</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Optiflow (Fisher &amp; Paykel Healthcare)</intervention_name>
    <description>This device delivers high-flow oxygen through nasal cannula</description>
    <arm_group_label>Nasal high-flow oxygen therapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Venturi mask</intervention_name>
    <description>This device delivers low-flow oxygen at predetermined concentrations</description>
    <arm_group_label>Venturi mask oxygen therapy</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age ≥ 18 years

          2. Mechanical ventilation &gt; 24 hours

          3. Signed Informed Consent

          4. Successful spontaneous breathing trial

          5. PaO2/FiO2 ratio ≤ 300 (or SpO2/FiO2 ratio ≤ 300 if SpO2 is lower than 98%) within 30
             min after extubation while breathing through a Venturi mask with a delivered FiO2 of
             30%

        Exclusion Criteria:

          1. Pregnancy

          2. Presence of tracheostomy

          3. Need for immediate post-extubation Non-Invasive Ventilation (&gt;3 consecutive failures
             of the spontaneous breathing trial and/or a PaCO2 &gt; 45 mmHg before the spontaneous
             breathing trial, with a respiratory rate ≥ 25/min)
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Salvatore Maurizio Maggiore, MD, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Catholic University of the Sacred Heart, A. Gemelli Hospital, Rome, Italy</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Salvatore Maurizio Maggiore, MD, PhD</last_name>
    <phone>+390630151</phone>
    <email>smmaggiore@rm.unicatt.it</email>
  </overall_contact>
  <location>
    <facility>
      <name>Sainte-Marguerite University Hospital</name>
      <address>
        <city>Marseille</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Laurent Papazian, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint Eloi University Hospital</name>
      <address>
        <city>Montpellier</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Samir Jaber, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Albert Prades, Res Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Matthieu Conseil, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Gerald Chanques, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Saint-Louis University Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elie Azoulay, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Virginie Lemiale, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>La Pitie-Salpetriere University Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Alexandre Demoule, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Julien Mayaux, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Louis Mourier University Hospital</name>
      <address>
        <city>Paris</city>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jean-Pierre Frat, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Arnaud Thille, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Céline Deletage</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Carole Guignon</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Evangelismos University Hospital</name>
      <address>
        <city>Athens</city>
        <country>Greece</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Spyros Zakynthinos, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico University Hospital</name>
      <address>
        <city>Bari</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Salvatore Grasso, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università del Piemonte Orientale, Ospedale della Carità</name>
      <address>
        <city>Novara</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Rosanna Vaschetto, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Catholic University of the Sacred Heart, A. Gemelli Hospital</name>
      <address>
        <city>Rome</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Salvatore Maurizio Maggiore, MD, PhD</last_name>
      <phone>+390630151</phone>
      <email>smmaggiore@rm.unicatt.it</email>
    </contact>
    <investigator>
      <last_name>Salvatore M Maggiore, Prof.</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Massimo Antonelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Le Molinette University Hospital</name>
      <address>
        <city>Turin</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Vito Marco Ranieri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Vito Fanelli, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Università del Piemonte Orientale, Sant'Andrea Hospital</name>
      <address>
        <city>Vercelli</city>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Paolo Navalesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Elizabeth Zavala, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Astrid Claramunt, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Jordi Mercadal, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
    <investigator>
      <last_name>Christian Heering, Res Nurse</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Sant Pau University Hospital</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Jordi Mancebo Cortes, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
    <investigator>
      <last_name>Indalecio Moran, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>France</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Spain</country>
  </location_countries>
  <verification_date>April 2014</verification_date>
  <lastchanged_date>April 4, 2014</lastchanged_date>
  <firstreceived_date>April 4, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Salvatore Maurizio MAGGIORE</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <keyword>Oxygen therapy</keyword>
  <keyword>Extubation</keyword>
  <keyword>Weaning</keyword>
  <keyword>Reintubation</keyword>
  <keyword>Acute respiratory failure</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Respiratory Distress Syndrome, Adult</mesh_term>
    <mesh_term>Respiratory Insufficiency</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
